An interventional study of Baloxavir Marboxil in Healthy Volunteer, sponsored by Hoffmann-La Roche. Completed at 1 site in China. Open to participants aged 20 Years to 59 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-08-11.
Sponsored by Hoffmann-La Roche · Not applicable, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This study will evaluate the pharmacokinetics, safety and tolerability of a single oral dose of baloxavir marboxil (40 mg or 80 mg) in healthy Chinese participants.
Hoffmann-La Roche is the lead sponsor of 2,102 studies on the registry; 89 are open to participants now.
Of its 330 completed or terminated interventional studies of FDA-regulated products, 248 (75%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Baloxavir Marboxil
Drug: Baloxavir Marboxil
Participants will receive either 40 mg or 80 mg of baloxavir marboxil on Day 1 as a single oral dose.
Also known as: Xofluza
Maximum Plasma Concentration (Cmax)
Baloxavir marboxil and baloxavir concentrations were analyzed by validated Liquid Chromatography with tandem mass spectrometry (LC-MS/MS). Non-compartmental analysis was employed to estimate the PK parameters.
Time frame: Pre-dose and at 1, 2, 3, 4, 5, 6, 8, 12, 24, 36, 48,72, 120, 168, 216, 264, and 336 hours post-dose
Time to Maximum Plasma Concentration (Tmax)
Baloxavir marboxil and baloxavir concentrations were analyzed by LC-MS/MS. Non-compartmental analysis was employed to estimate the PK parameters.
Time frame: Pre-dose and at 1, 2, 3, 4, 5, 6, 8, 12, 24, 36, 48,72, 120, 168, 216, 264, and 336 hours post-dose
Area Under the Concentration to Time Curve From Time 0 to Infinity (AUC0-inf)
Baloxavir marboxil and baloxavir concentrations were analyzed by LC-MS/MS. Non-compartmental analysis was employed to estimate the PK parameters.
Time frame: Pre-dose and at 1, 2, 3, 4, 5, 6, 8, 12, 24, 36, 48,72, 120, 168, 216, 264, and 336 hours post-dose
Area Under the Concentration to Time Curve From Time 0 to Last Quantifiable Concentration (AUC0-last)
Baloxavir marboxil and baloxavir concentrations were analyzed by LC-MS/MS. Non-compartmental analysis was employed to estimate the PK parameters.
Time frame: Pre-dose and at 1, 2, 3, 4, 5, 6, 8, 12, 24, 36, 48,72, 120, 168, 216, 264, and 336 hours post-dose
Area Under the Concentration to Time Curve From Time 0 to Time t (AUC0-t)
Time t may be chosen as a time point where evaluable concentrations are available in at least 90% of participants. Baloxavir marboxil and baloxavir concentrations were analyzed by LC-MS/MS. Non-compartmental analysis was employed to estimate the PK parameters.
Time frame: Pre-dose and at 1, 2, 3, 4, 5, 6, 8, 12, 24, 36, 48,72, 120, 168, 216, 264, and 336 hours post-dose
Terminal Elimination Half-Life (T1/2)
Baloxavir marboxil and baloxavir concentrations were analyzed by LC-MS/MS. Non-compartmental analysis was employed to estimate the PK parameters.
Time frame: Pre-dose and at 1, 2, 3, 4, 5, 6, 8, 12, 24, 36, 48,72, 120, 168, 216, 264, and 336 hours post-dose
Apparent Total Oral Clearance (CL/F)
Baloxavir marboxil and baloxavir concentrations were analyzed by LC-MS/MS. Non-compartmental analysis was employed to estimate the PK parameters.
Time frame: Pre-dose and at 1, 2, 3, 4, 5, 6, 8, 12, 24, 36, 48,72, 120, 168, 216, 264, and 336 hours post-dose
Apparent Oral Volume of Distribution (Vz/F)
Baloxavir marboxil and baloxavir concentrations were analyzed by LC-MS/MS. Non-compartmental analysis was employed to estimate the PK parameters.
Time frame: Pre-dose and at 1, 2, 3, 4, 5, 6, 8, 12, 24, 36, 48,72, 120, 168, 216, 264, and 336 hours post-dose
Plasma Concentrations 24 (C24), 48 (C48), and 72 Hours (C72) Postdose
Baloxavir marboxil and baloxavir concentrations were analyzed by LC-MS/MS. Non-compartmental analysis was employed to estimate the PK parameters.
Time frame: 24, 48 and 72 hours postdose
Percentage of Participants With Adverse Events (AEs)
Time frame: Up to Day 15
| Milestone | Baloxavir Marboxil 40 mg | Baloxavir Marboxil 80 mg |
|---|---|---|
| Started | 16 | 16 |
| Completed | 16 | 16 |
| Not completed | 0 | 0 |
Baloxavir marboxil and baloxavir concentrations were analyzed by validated Liquid Chromatography with tandem mass spectrometry (LC-MS/MS). Non-compartmental analysis was employed to estimate the PK parameters.
| nanogram per milliliter (ng/mL) | Baloxavir Marboxil 40 mg | Baloxavir Marboxil 80 mg |
|---|---|---|
| Baloxavir Marboxil | — | 0.5133 ± 3.7 |
| Baloxavir | 107.6 ± 24.2 | 206.9 ± 38.3 |
Baloxavir marboxil and baloxavir concentrations were analyzed by LC-MS/MS. Non-compartmental analysis was employed to estimate the PK parameters.
| hours (h) | Baloxavir Marboxil 40 mg | Baloxavir Marboxil 80 mg |
|---|---|---|
| Baloxavir Marboxil | — | 5.50 (5.00 to 6.00) |
| Baloxavir | 4.00 (3.00 to 6.00) | 4.00 (3.00 to 5.00) |
Baloxavir marboxil and baloxavir concentrations were analyzed by LC-MS/MS. Non-compartmental analysis was employed to estimate the PK parameters.
| ng*h/mL | Baloxavir Marboxil 40 mg | Baloxavir Marboxil 80 mg |
|---|---|---|
| Baloxavir | 6955 ± 25.5 | 9643 ± 29.4 |
Baloxavir marboxil and baloxavir concentrations were analyzed by LC-MS/MS. Non-compartmental analysis was employed to estimate the PK parameters.
| ng*h/mL | Baloxavir Marboxil 40 mg | Baloxavir Marboxil 80 mg |
|---|---|---|
| Baloxavir | 6442 ± 24.3 | 9218 ± 29.2 |
Time t may be chosen as a time point where evaluable concentrations are available in at least 90% of participants. Baloxavir marboxil and baloxavir concentrations were analyzed by LC-MS/MS. Non-compartmental analysis was employed to estimate the PK parameters.
| ng*h/mL | Baloxavir Marboxil 40 mg | Baloxavir Marboxil 80 mg |
|---|---|---|
| Baloxavir | 6442 ± 24.3 | 9218 ± 29.2 |
Baloxavir marboxil and baloxavir concentrations were analyzed by LC-MS/MS. Non-compartmental analysis was employed to estimate the PK parameters.
| hours (h) | Baloxavir Marboxil 40 mg | Baloxavir Marboxil 80 mg |
|---|---|---|
| Baloxavir | 99.74 ± 18.0 | 88.89 ± 17.1 |
Baloxavir marboxil and baloxavir concentrations were analyzed by LC-MS/MS. Non-compartmental analysis was employed to estimate the PK parameters.
| Liters (L)/h | Baloxavir Marboxil 40 mg | Baloxavir Marboxil 80 mg |
|---|---|---|
| Baloxavir | 4.866 ± 25.5 | 7.019 ± 29.4 |
Baloxavir marboxil and baloxavir concentrations were analyzed by LC-MS/MS. Non-compartmental analysis was employed to estimate the PK parameters.
| L | Baloxavir Marboxil 40 mg | Baloxavir Marboxil 80 mg |
|---|---|---|
| Baloxavir | 700.1 ± 26.6 | 900.1 ± 31.4 |
Baloxavir marboxil and baloxavir concentrations were analyzed by LC-MS/MS. Non-compartmental analysis was employed to estimate the PK parameters.
| ng/mL | Baloxavir Marboxil 40 mg | Baloxavir Marboxil 80 mg |
|---|---|---|
| Baloxavir C24 | 56.40 ± 22.8 | 92.01 ± 27.9 |
| Baloxavir C48 | 41.38 ± 22.9 | 60.33 ± 33.2 |
| Baloxavir C72 | 29.27 ± 25.0 | 41.78 ± 31.6 |
| percentage of participants | Baloxavir Marboxil 40 mg | Baloxavir Marboxil 80 mg |
|---|---|---|
| Percentage of Participants With Adverse Events (AEs) | 18.8 | 68.8 |
Collected over Baseline up to Day 15. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Baloxavir Marboxil 40 mg | 0/16 (0%) | 0/16 (0%) | 3/16 (18.8%) |
| Baloxavir Marboxil 80 mg | 0/16 (0%) | 0/16 (0%) | 11/16 (68.8%) |
| Event | Baloxavir Marboxil 40 mg | Baloxavir Marboxil 80 mg |
|---|---|---|
| Upper respiratory tract infectionInfections and infestations | 0/16 | 3/16 |
| Blood bilirubin increasedInvestigations | 1/16 | 2/16 |
| Blood uric acid increasedInvestigations | 1/16 | 2/16 |
| DizzinessNervous system disorders | 1/16 | 2/16 |
| DiarrhoeaGastrointestinal disorders | 0/16 | 2/16 |
| Electrocardiogram T wave abnormalInvestigations | 0/16 | 1/16 |
| Defect conduction intraventricularCardiac disorders | 0/16 | 1/16 |
| Ventricular extrasystolesCardiac disorders | 0/16 | 1/16 |
| FatigueGeneral disorders | 0/16 | 1/16 |
| HaematuriaRenal and urinary disorders | 0/16 | 1/16 |
| Age, Continuous(years) | Baloxavir Marboxil 40 mg | Baloxavir Marboxil 80 mg | Total |
|---|---|---|---|
| Mean | 28.2 ± 5.82 | 29.5 ± 6.09 | 28.8 ± 5.90 |
| Sex: Female, Male(Participants) | Baloxavir Marboxil 40 mg | Baloxavir Marboxil 80 mg | Total |
|---|---|---|---|
| Female | 0 | 0 | 0 |
| Male | 16 | 16 | 32 |
| Race (NIH/OMB)(Participants) | Baloxavir Marboxil 40 mg | Baloxavir Marboxil 80 mg | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 16 | 16 | 32 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 |
| White | 0 | 0 | 0 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Jun 2019 to primary completion in Jul 2019, 0 months.
Results were first posted in Jun 2020, 11 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Baloxavir